Kei Nakamura1,2, Hiroshi Nakamura2, Kazuyo Tohyama2, Chikashi Takara2, Chiho Iseki2, Mark Woodward3,4,5, Kunitoshi Iseki2. 1. Urasoe General Hospital, Okinawa, Japan. 2. Nakamura Clinic, Urasoe, Okinawa, Japan. 3. The George Institute for Global Health, Imperial College, London, United Kingdom. 4. The George Institute for Global Health, University of New South Wales, Australia. 5. Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland.
Abstract
STUDY OBJECTIVES: Continuous positive airway pressure (CPAP) improves quality of life in patients with obstructive sleep apneas. However, the long-term benefit in all-cause mortality and cardiovascular death are limited among Japanese. METHODS: We conducted a retrospective study of patients treated in our sleep clinic in Okinawa, Japan. All patients with full-scale polysomnography from September 1990 to December 2010 were investigated in terms of outcomes such as death (dates and causes of death) between 2012 and 2013 by chart review, telephone calls, and letters of inquiry. Propensity-score matching was performed to balance baseline characteristic differences between a CPAP user group and a nonuser group. The primary outcomes were all-cause mortality and a composite of cardiovascular disease mortality, such as heart disease and stroke, between the two groups. RESULTS: The CPAP user group, almost double in number, had more severe obstructive sleep apnea, more comorbidities, smoking, and alcohol consumption compared to the nonuser group but no significant difference in Epworth Sleepiness Scale. Propensity-score matching selected 1,274 of 4,519 patients as the CPAP user group and 1,274 of 2,128 as the CPAP nonuser group. Mean age of the patients was 52.3 (±13.5) years and 79% were men. After a median follow-up of 79 (interquartile interval, 24 to 128) months in the CPAP user group and 73.5 (interquartile interval, 26 to 111) in the non-CPAP group, death from all causes occurred in 53 (4.2%) patients in CPAP user group and in 94 (7.4%) patients in CPAP nonuser group. The leading cause of death was malignancy in each group. The hazard ratios for all-cause mortality and cardiovascular disease deaths were 0.56 (95% confidence interval (CI), 0.41-0.78) and 0.54 (95% CI, 0.28-1.03) between CPAP user group and CPAP nonuser group, respectively. CONCLUSIONS: In obstructive sleep apnea patients, CPAP use was associated with lower all-cause mortality.
STUDY OBJECTIVES: Continuous positive airway pressure (CPAP) improves quality of life in patients with obstructive sleep apneas. However, the long-term benefit in all-cause mortality and cardiovascular death are limited among Japanese. METHODS: We conducted a retrospective study of patients treated in our sleep clinic in Okinawa, Japan. All patients with full-scale polysomnography from September 1990 to December 2010 were investigated in terms of outcomes such as death (dates and causes of death) between 2012 and 2013 by chart review, telephone calls, and letters of inquiry. Propensity-score matching was performed to balance baseline characteristic differences between a CPAP user group and a nonuser group. The primary outcomes were all-cause mortality and a composite of cardiovascular disease mortality, such as heart disease and stroke, between the two groups. RESULTS: The CPAP user group, almost double in number, had more severe obstructive sleep apnea, more comorbidities, smoking, and alcohol consumption compared to the nonuser group but no significant difference in Epworth Sleepiness Scale. Propensity-score matching selected 1,274 of 4,519 patients as the CPAP user group and 1,274 of 2,128 as the CPAP nonuser group. Mean age of the patients was 52.3 (±13.5) years and 79% were men. After a median follow-up of 79 (interquartile interval, 24 to 128) months in the CPAP user group and 73.5 (interquartile interval, 26 to 111) in the non-CPAP group, death from all causes occurred in 53 (4.2%) patients in CPAP user group and in 94 (7.4%) patients in CPAP nonuser group. The leading cause of death was malignancy in each group. The hazard ratios for all-cause mortality and cardiovascular disease deaths were 0.56 (95% confidence interval (CI), 0.41-0.78) and 0.54 (95% CI, 0.28-1.03) between CPAP user group and CPAP nonuser group, respectively. CONCLUSIONS: In obstructive sleep apnea patients, CPAP use was associated with lower all-cause mortality.
Authors: Daniel J Gottlieb; Gayane Yenokyan; Anne B Newman; George T O'Connor; Naresh M Punjabi; Stuart F Quan; Susan Redline; Helaine E Resnick; Elisa K Tong; Marie Diener-West; Eyal Shahar Journal: Circulation Date: 2010-07-12 Impact factor: 29.690
Authors: Michael Arzt; Terry Young; Laurel Finn; James B Skatrud; T Douglas Bradley Journal: Am J Respir Crit Care Med Date: 2005-09-01 Impact factor: 21.405
Authors: R Doug McEvoy; Nick A Antic; Emma Heeley; Yuanming Luo; Qiong Ou; Xilong Zhang; Olga Mediano; Rui Chen; Luciano F Drager; Zhihong Liu; Guofang Chen; Baoliang Du; Nigel McArdle; Sutapa Mukherjee; Manjari Tripathi; Laurent Billot; Qiang Li; Geraldo Lorenzi-Filho; Ferran Barbe; Susan Redline; Jiguang Wang; Hisatomi Arima; Bruce Neal; David P White; Ron R Grunstein; Nanshan Zhong; Craig S Anderson Journal: N Engl J Med Date: 2016-08-28 Impact factor: 91.245
Authors: Catriona McDaid; Kate H Durée; Susan C Griffin; Helen L A Weatherly; John R Stradling; Robert J O Davies; Mark J Sculpher; Marie E Westwood Journal: Sleep Med Rev Date: 2009-04-10 Impact factor: 11.609
Authors: Terry Young; Laurel Finn; Paul E Peppard; Mariana Szklo-Coxe; Diane Austin; F Javier Nieto; Robin Stubbs; K Mae Hla Journal: Sleep Date: 2008-08 Impact factor: 5.849
Authors: Chitra Lal; Indu Ayappa; Najib Ayas; Andrew E Beaudin; Camilla Hoyos; Clete A Kushida; Marta Kaminska; Anna Mullins; Sharon L Naismith; Ricardo S Osorio; Craig L Phillips; Ankit Parekh; Katie L Stone; Arlener D Turner; Andrew W Varga Journal: Ann Am Thorac Soc Date: 2022-08
Authors: Jean-Louis Pépin; Sébastien Bailly; Pierre Rinder; Dan Adler; Adam V Benjafield; Florent Lavergne; Anne Josseran; Paul Sinel-Boucher; Renaud Tamisier; Peter A Cistulli; Atul Malhotra; Pierre Hornus Journal: Chest Date: 2022-02-15 Impact factor: 10.262